Nivolumab-related cutaneous sarcoidosis in a patient with lung adenocarcinoma.

Birnbaum, Mathew R; Ma, Michelle W; Fleisig, Sarah; Packer, Stuart; Amin, Bijal D; Jacobson, Mark; McLellan, Beth N.

Afiliação

Birnbaum MR; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
Ma MW; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
Fleisig S; Department of Medicine, Division of Hematology/Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
Packer S; Department of Medicine, Division of Hematology/Oncology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
Amin BD; Department of Pathology, Division of Dermatology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
Jacobson M; Department of Pathology, Division of Dermatology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.
McLellan BN; Department of Medicine, Division of Dermatology, Albert Einstein College of Medicine/Montefiore Medical Center, Bronx, New York.

JAAD Case Rep ; 3(3): 208-211, 2017 May.

Article em En | MEDLINE | ID: mdl-28443311

Palavras-chave

CTLA-4, cytotoxic T-lymphocyte-associated protein 4; PD-1, programmed cell death-1; PD-L, programmed cell death ligand; immune checkpoint inhibitors; immune-related adverse events; immunotherapy; irAE, immune-related adverse event; nivolumab; programmed cell death-1; sarcoidosis

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article